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Cover: Belisa Diaz assists Anjanette Watson.  
            Soon to be graduates lined up backstage. 
            Martha Rodriquez Sandoval receives congratulations from UT M.D. Anderson Cancer Center  
 President John Mendelsohn and Health Science Center President M. David Low. 
All Commencement photos courtesy of Ms. Joann Sowell 
New Fulbright Scholar, 4th year Ph.D. student Sally Kim, (right) will travel 
to Germany for research work at the prestigious Max Planck Institute known 
for its work in neuroscience.  Ms. Kim is doing research studies on the spatial 
and temporal dynamics of calmodulin in neurons.  M. Neal, Waxham, Ph.D., 
(left) is Kim's advisor. 
The Rosalie B. Hite Fellowship 2000/2001 recipients in the GSBS are: Mary Coolbaugh-Murphy in Molecular Genetics,  
Michael Siciliano, Ph.D., Advisor; Joshua Krumenacker in Pharmacology-Physiology, Ferid Murad, Ph.D., Advisor; and 
Shi, Zheng (Jane) in Experimental Therapeutics; William Plunkett, Ph.D., Advisor.  This prestigious honor provides a 
$20,000 award for the year to each recipient.   
The Aaron Blanchard Award winner for 2000 was Steven McCullough.  McCullough, now a Ph.D. was a 5th year stu-
dent working in cancer therapy, Richard Wendt III, Ph.D., Advisor.  The Blanchard Award is named for a GSBS student 
who succumbed to brain cancer in 1998. 
       AWARD WINNERS 
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Dean’s Notes 
. . .On "using your left hand" 
 
The day of commencement is always special, but this year it was doubly special for me, and I would 
like to share that story with you.  The GSBS Commencement ceremonies on that day were wonderful: 
the students were great, the parents and faculty were beaming with pride, and the speaker, Dr. Michael 
McClure from NIH, gave a fine address (see pages 5-8 for an excerpt).  However, the story I want to 
share took place in suburban Chicago that evening. 
 
Several months before, I received a phone call from Dwight, a guy I played basketball and football with 
in the early 60's.  He said that he had recently seen one of our favorite high school coaches around the 
old neighborhood and that "Coach" was in the early stages of Alzheimer's disease.  This prompted 
Dwight to organize a dinner for the old gang from high school as a salute to our several surviving 
coaches before memories of their coaching days were completely lost.  I said I would be there and pro-
ceeded to make travel plans to fly to Chicago immediately after the GSBS Commencement.  If I looked 
a little anxious on stage during the ceremony, it was because I had a very tight travel connection to 
make at George Bush Intercontinental Airport. 
 
Fortunately, all went well, and I arrived at the appointed restaurant in my hometown of Cicero, Illinois, 
just in time for the festivities.  I had anticipated that there might be 20-30 guys from my class in atten-
dance, but I was stunned to find a room with 200-300 middle aged ex-high school athletes from the en-
tire decade of the 1960's - many of whom came from such far away places as California, Texas, Wash-
ington state, New England, Florida, Hawaii, and Canada.  I immediately thought to myself, what in-
spired all of these people, most of whom had not even been starting players, to travel so far for a couple 
of retired coaches who had never won a conference championship (probably more of a comment on the 
team members than the coaches!)? 
 
As I walked into the gathering, the first person I met was my freshman basketball coach.  He had been a 
Marine drill sergeant prior to becoming a teacher, and he greeted me with a booming voice, "Stancel, 
how's your left hand doing?" Let me explain.  I am right-handed, and during basketball season my en-
tire freshmen year, coach kept stressing that I should practice using my left hand since it is more diffi-
cult for opposing players to guard you if you can dribble and shoot with both hands.  I tried and tried, 
but despite my best efforts, I missed numerous left-handed lay-ups in games that year.  Even though 
several of those misses cost us games, the coach was patient and encouraging, and he kept insisting that 
I use my left hand because it would be better for my basketball career when I got to the varsity.  In that 
instant, 40 years later, I realized for the first time that coach was more interested in my future career 
than his personal won-lost record; a split second later, I realized why several hundred guys, most of 
whom had not even been starters, came from thousands of miles away to a dinner for some old coaches 
with fading memories who never won a championship.  I answered his question, "Just fine coach, and 
thank you." 
 
That experience prompted me to use this opportunity to salute all our great faculty "coaches" who keep 
encouraging our GSBS students to "use your left hand", even if it costs you something in the short 
term.  That's what coaching, and teaching, is all about.  Thanks to all of you for making sure our stu-
dents have the best chance for great careers in science and research - that's the won-lost record that 
counts the most for us as GSBS faculty members! 
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MESSAGE TO THE CLASS OF 2000 
Steven J. Norris, Ph.D., Faculty President 
Dear graduating students, family members, friends, colleagues, and  
distinguished guests: 
It is indeed an honor to bring you the congratulations and best wishes of the GSBS 
Faculty.  In case it has been unclear to the family members and friends how your fa-
vorite graduate student has been spending their days, nights, and weekends over the 
past several years, I thought I would start by briefly summarizing what a graduate de-
gree in Biomedical Sciences means.  A Ph.D. degree means that the student has 
learned to assimilate and distill the scientific information in a particular area, formulate 
a hypothesis addressing an aspect of that topic, design an experimental approach, inter-
pret the resulting data, and present and publish their findings for the scientific commu-
nity and general public.  A Masters degree is much the same, except you have less time to do it!  This process, which de-
fines what it means to be an independent investigator, will be repeated throughout your lifetime.  Although the knowledge 
you acquire along the way is important, the process itself is vital.  In this case, the CPU is more essential than the hard 
drive. 
Every faculty member has a heart to heart talk with their graduate student when they complete their degree, and this is a 
very satisfying time when the advisor can loosen the reins and provide the last few pearls of wisdom.  I distinctly remem-
ber my final meeting with my mentor, Jim Miller at UCLA, and in particular his parting words of advice: that I should 
always wear matching socks.  (I’ve tried to hold to that, with mixed success).  I’ve never had the privilege of giving a final 
heart to heart talk to 36 graduating students, so I plan to take full advantage of it. 
My advice is neither unique nor profound, resembling instead three well-worn coins in a familiar fountain.  First, find joy 
in small increments of success.  Progress in science can be frustrating, often moving at a snail’s (Aplysia’s?) pace.  At 
times we feel like we’re making the sand that will go in the brick that makes up a building, but sometimes the smallest 
discoveries are the most important.  Second, ask important questions.  It is easy in science to follow familiar trails, going 
through the valleys rather than conquering the mountains.  Take a few minutes each day to ask yourself: Is what I’m doing 
really addressing the central question of my field?  Like the legendary ninja, don’t be afraid to rip the heart out of your 
scientific area (not your competitor) rather than just pat it on the shoulder.  Third, share your excitement and enthusiasm 
with those around you.  You all know the moment: you reach into the film developer and pull out THE AUTORAD. The 
one that proves the concept you’ve been working on for the past two years.  Do you keep that to yourself?  NO!!  I have 
colleagues I can always go to (or call on the phone) and, jumping up and down, tell “LOOK WHAT WE’VE FOUND!” 
They’ll say, “That’s great, that’s fantastic!” then after five minutes of jumping up and down ask “What does it mean?”  
Think back to your favorite teachers or fellow students, and I believe you’ll find that they convey that excitement and 
sense of discovery. 
There are times when all scientists get down, when our role seems to change from “discoverer of future knowledge” to 
“expeditor.”  When I get down like that, I think back to the time in high school when I reached down, picked a blade of 
grass and thought, “There is more wonder in this blade of grass then can be understood in a lifetime.”  Students, keep that 
wonder the rest of your lives.  Faculty, if you have let that sense of wonder slip away, recapture it and continue to pass it 
on to those around you.  In fact, everyone in this room, regardless of your background, can appreciate the wonder of life. 
Next time you wake up, you can look around and think, “Wow, this is really neat.”  Thank you, and best wishes to all of 
you for your continued success on the heels of this major achievement. 
 
Like the legendary ninja, don’t be afraid to rip the 
heart out of your scientific area (not your competitor) 
rather than just pat it on the shoulder. 
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2000 Commencement Address 
Third Millennium Science: Research in a Brave New World 
 
Michael E. McClure, Ph.D., Distinguished Alumnus  
Chief, Organs and Systems Toxicology Branch, Division of Extramural Re-
search and Training, National Institute of Environmental Health Sciences 
Thank you Presidents Mendelsohn and Low, Dean Stancel and the Dean’s Council 
of the Graduate School of Biomedical Sciences for the opportunity to share a few 
views of the state of biomedical research on the dawn of our entering the next mil-
lennium. 
The GSBS Class of 2000 will step over the threshold into a professional world of 
vastly different potential than the horizon before me just 30 years ago.  The knowl-
edge we have gained in FUNCTIONAL GENOMICS—a field that touches every other field in the life sciences—will 
change the way we look at and live with every other person, animal, plant, bacteria and virus on this planet.  For the first 
time, humans are able to extensively study, design, and build on a molecular level to such a degree that we will soon be 
able to directly and deliberately influence our own evolution and that of the other species with which we share this earth.  
The 21st century poses considerable challenges for the next generation of biomedical scientists in carrying us further to-
ward sustainable development of our species, the other species upon which we depend, and the environment in which we 
live.  How we do this as a nation will be the major test of our humanity in the next century. 
It is stunning to realize that on an earth that is hundreds of billions of years old, where life has been evolving for at least 
500 millions of years, that modern mankind, a relative late-comer in the relatively short span of about 300,000 years has 
grown from two individuals—mitochondrial Eve and centrosomal Adam—to multiple billions and become wholly domi-
nant of the earth, its resources, and its co-habiting life forms.  To add perspective to this “short span,” if the age of the 
earth were compressed into a 24-hour day, we modern humans would have lived as a species for about three seconds.  
Even more strikingly, the age of literacy that launched science as a tool of mankind has existed for a mere 3.5 millisec-
onds.  In this “eyeblink” of evolutionary time, science has conferred upon man a power over life forms that lies outside 
the jurisdiction of natural laws of evolution—a power that may soon enable such laws to be rewritten by man to suit him-
self.  This is the promise of the year 2000 as we move through the transition between the old age of GENETICS and the 
new one of GENOMICS. 
By the year 2030, one-quarter of the U.S. Population will be over the age of 65.  Life expectancy by the year 2040 is pre-
dicted to be 76 for men and 84 for women.  Changing aspects of our reproductive strategy and life expectancy raise new 
medical challenges for the prevention and treatment of aging-related diseases arising from the expression of individual 
genetic susceptibilities that may be triggered or exacerbated by adverse environmental factor exposures in an increasingly 
adverse environment.  Medically speaking, we are rapidly approaching the age of GERIATRIC GENOMICS. 
Alexander Pope in his work entitled “Essays on Criticism” states two truths that I have held in memory since I read them.  
The first is, “The best study of man, is man himself,” and the second is “Drink deep or taste not of the Pierian spring for 
shallow thoughts intoxicate the brain and drinking deeply sobers us again.”  These thoughts reflect the two most important 
aspects of life science research for our human population in the next century.  First, what post-genomic “studies of man” 
should be developed to better the human condition, i.e., the medical biotechnology aspect, and second, what shouldn’t be 
done with it, i.e., the bioethics aspect. 
It is now estimated that at least 6 billion souls live together on this earth in the year 2000.  Indeed, the UN announced 
that the first identified “Y6B” baby was born on October 12, 1999.  The UN Population Fund Annual 1998 Report states 
that the number will be about 9.4 billion by 2050.  At the rate estimated, we are newly adding 174 people to the earth 
every minute.  The impact of the growth of the human population is already seen in the increasing demand for consumable 
resources and the increasing depletion of the variety of available resources.  From the 6 billion souls here in 2000, there 
will be generated a sufficiently increased global population quantity to visibly stress the carrying capacity of the earth in 
our not too distant future.  There will be an increasing impact of unsustainable consumption issues that forces substantial 
lifestyle changes and choices.  Science will be once again put to the test in finding solutions for achieving sustainable de-
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velopment. 
 
Human population growth effects also have been linked to a substantial loss of biodiversity-the accumulated wealth of the 
diverse plant and animal species that share this earth with us.  Of particular note is that the closest genetic primate to our-
selves on this planet, chimpanzees, whose DNA differs from ours by about 1.5%, are globally diminishing in numbers at an 
alarming rate.  The chimpanzee like many other feral species lives in areas increasingly encroached upon by the developing 
resource needs of mankind.  What secrets of our own primate history will disappear with the chimpanzee?  As elegantly ex-
pressed by Jonathan Marks in his recent article entitled 98% Alike “— It isn’t too hard to tell Jane Goodall from the chimpan-
zees she studies.  She is the one with the long legs, short arms, prominent forehead, whites in her eyes and a significant 
amount of hair only on her head.  She is the one who walks, talks, ciphers and wears clothing.  All of these traits of Goodall 
arise from the 1.5% of the DNA difference between them…and this defines a colossal mystery yet to be solved.” 
 
Of perhaps greatest concern for the future are the population and environment issues of public health to be resolved from 
2000 onward.  Being placed in a circumstance where our population members are forced by the pressure of increasingly re-
duced vital resources to choose between longevity of life or controlled birth rates, either voluntarily or by coercion, seems an 
adequate enough reason to vigorously continue federal support for population and environmental health sciences research.  It 
does not seem unreasonable to expect a second revolution in these research areas built on the new principles of genetic medi-
cine that are only now beginning to unfold.  It has, in fact, already begun. 
 
What are these new tools of genetic medicine? 
 
The federal Human Genome Project will conclude its effort to sequence a human genome in 2003 if the current schedule 
holds.  The known sequences for the 100,000 or so genes that comprise the human genome will permit genetic studies of a 
molecular complexity previously impossible to do.  From these 100,000 genes, there could be 20 to 100 million protein 
forms.  We only know the function of about 5000 proteins at present and the future holds much exploratory work in increas-
ing this number.  It was reported recently that pilot microarray chips holding over 400,000 probes have been prepared. With 
such a powerful tool, one will be able to measure changing patterns of gene activity over the period of time that a cell under-
goes a critical differentiation step or physiological function. Super gene chips will make it possible to observe the gain or loss 
of genetic function and predict susceptibility to biological changes such as those induced by a drug, chemical or environ-
mental toxicant.  Chip-based studies on the earliest cells, that direct our growth and development—stem cells—will permit 
studies on the cascade of sequential gene expression changes that are required to develop a specialized cell, e.g., a heart mus-
cle cell, and define the role of signaling messenger molecules in directing the unfolding developmental program.  With such 
knowledge, the bioengineering of the unique tissues of our bodies will become feasible. 
 
Over the next decade, rapid advances will be made in harnessing the power of computerized bioinformatic protocols to proc-
ess the massive data processing needed to analyze DNA microarray chip patterns presenting complex polygenic gene expres-
sion profiles—a genetic signature—for an individual’s unique physiological or pathophysiological status.  Real-time multidi-
mensional gene expression microarray analyses for organ or tissue functional status will be able to be analyzed in time spans 
feasible for efficient use in research and clinical applications.  Pilot accomplishments in this area have already been reported 
this year.  This genomics approach will also interface with the new field of COMBINATORIAL CHEMISTRY AND PRO-
TEOMICS.  On earth today there are about 100 million species with an average of perhaps 100,000 genes per species, so the 
total protein diversity in the biosphere is about 100 trillion kinds of proteins.  It is now possible to make 100 trillion random 
proteins simultaneously in a test tube all at once to screen them for potential drug, vaccine or enzyme products.  Combinato-
rial chemistry is going to provide the molecular tools that we need to find specific proteins in specific ways that have specific 
activities. 
 
How will these new technologies be applied to public health problems? 
 
In the immediate future of genetic medicine we will see PHARMACOGENETICS mature as a field and provide health care 
specialists with the ability to evaluate the effect of interindividual genetic variation on drug efficacy and safety.  The day will 
come when a patient will present their credit card-sized individual gene chip identification card to a practicing physician for 
an in-office evaluation of side effect risks for the pharmaceutical drug he/she is prescribing.  The day is dawning when the 
field of PHARMACOGENOMICS will provide health care scientist-clinician teams specialized in the selection of optimum 
treat for individual patients based upon that individual’s genetic or expressed molecular product profile.  In the environmental 
health area we will see the newly emerging field of TOXICOGENOMICS develop approaches to monitor for and treat the 
effects of toxic environmental agent to factor exposures before such exposures can trigger or adversely influence an exposure-
linked disease. The future of genetic medicine-based health care lies in the intersecting teamwork of professional scientists 
skilled in diagnostic, therapeutic and information sciences.   
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Given the “Geriatric Genomics” prediction and its linkage of environmental exposure, genetic susceptibility and extended 
time for expression, we can expect to see a “greening” of biomedical research.  In the terminology of Vice President Al Gore, 
that is to say, research aimed at the development of clinical applications for the intervention and prevention of environmen-
tally caused or exacerbated morbidity and mortality. 
 
The genomic technology will provide the tools for toxicogenomic approaches to develop the means to:  1) Identify genetically 
susceptible individuals at risk of defined toxicant effects.  2) Block the ability of environmental toxins to cause damage by 
therapeutically activating toxin-binding proteins in susceptible individuals. 3) Therapeutically speed up the rate that naturally 
occurring enzymes detoxify substances. 4) Enhance the ability of the human body to actually repair environmentally damaged 
DNA.  
 
It is only when the public realizes how relevant a science event is to their lives that scientists have an easy time bridging 
the gap to the national consciousness.  We can expect that genetic medicine, functional genomics and tissue engineering will 
burst upon the national lay consciousness in the next decade.  We face a critical communication challenge in bridging science 
and the citizen. Although stem cell and cloning research has been around for some time in science, it has only become an is-
sue at the level of the national consciousness over the last several years. 
 
By way of example, consider animal cloning, which was the great event of the 20th century by many accounts, and it evoked 
an extraordinary societal reaction to a science outcome that is only rarely seen.  The birth of Dolly provoked worldwide dis-
cussions and a plethora of reactions ranging from panic to euphoria.  The technology has become like the sorcerer’s broom, 
taking on a life of its own beyond the control of the practitioners of the technology.   
 
The rapid progress reported for the technology with monkeys and mice further raised the public consciousness of the pros-
pects for cloning of genetically modified animals, including, possibly, The HUMAN.  The human cloning prospects generated 
an immense socio-political response ranging from congressional hearings and national legislation to more than 40 legislative 
bills at the state level and the signed agreement reached by 19 countries regarding prohibitive policies toward human cloning. 
Public reporting in newspapers and magazines on cloning exploded worldwide.  Scores of new books were published which 
added to available books and created a publisher’s list total of 101 as of January 1999, including Danielle Steele’s book The 
Clone and I.  From the time of Gina Kolata’s first post-Wilmut book entitled Clone in 1998, fourteen technical books have 
appeared, the last in March 2000, ironically, being that of Ian Wilmut, the cloner of Dolly.  Including “Mini-Me” in The Spy 
Who Shagged Me, human clones were prominently feature in the six movies made in this period which joined the prior list of 
32 dating from 1935-1998.  Music about clones was issued (Fear Factory eight-song special cassette tape).  Made for TV 
movies appeared (Cloned). Even “la femme Nakita” was almost cloned.  Hundreds of web homepages appeared with some, 
like the USA Weekend WebPages, surveying public opinion by soliciting votes for or against human cloning and others for 
educating children on the techniques.  All this, not to mention the hundreds of published cartoon artworks and numerous ad-
vertising commercials referencing cloning made it the social science- or science social event of the year. 
 
Human clones have existed throughout mankind’s history, they are monozygotic twins.  My father was a clone and I bear the 
genes of a clone in my own body.  We need not await the appearance of human clones in society that are produced by human 
technology since, in fact, they are here.  Assisted reproductive technology has apparently been actually producing human 
clones for several decades now. Dolly and the dozens of cloned animal reports that followed her brought to the public mind a 
clear understanding of the potential use of nuclear genomic reprogramming or directed genomic programming to agricultural, 
pharmaceutical and medical applications.  These are leading areas of research today with eminent commercial impact. 
 
Just to consider two of these potentials it is interesting to note that the trade in human drug proteins produced by a trans-
genic cow, sheep or goat is a potentially multi-billion dollar business.  Cloning can shorten the time required to generate a 
production herd by eliminating the slow process of building a herd by conventional animal husbandry technology.  A small-
cloned herd of such goats could easily supply the world’s need for the protein drug.  A second potential, currently embroiled 
in national debate and a focus of congressional infighting linked to the next NIH Research Budget, is that of stem cell re-
search with its prospects for an industry with a multi-billion dollar annual market.  The emergence of technology to control 
the nuclear programming of stem cells will yield specialized cells for the cell therapy of certain diseases like Parkinson’s dis-
ease or diabetes.  It will also lead to technology for spinal cord and nervous tissue damage repair, as well as fuel research in 
tissue engineering for treating clinical disease or tissue or organ injury that is beyond cell therapy.  
 
The closing of the genetic century heralds the beginning of the genomic century.  It is here and we are in it.  The transition 
has ushered in new challenges to science for ensuring the means of our living and reproducing responsibly in a healthy global 
relationship with each other and the environment.  The means are at hand and the hands that will apply them are the young 
investigators graduating from our nations’ graduate schools this year. 
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In closing, I would like to thank the early GSBS Faculty, all remembered but too numerous to mention, of that ancient era of 
my graduate education in the GSBS in the 1960’s.  This was the defining moment in my professional life.  It was then and 
there that the awakening occurred that opened my eyes, my mind and my heart to the realities of health science research as a 
career.  The booming Texas Medical Center environment of that era, and the UT-GSBS in particular, provided a panoply of 
exciting scientific training and research opportunities.  The education, training, and experience I gained during my time with 
the UT-M.D. Anderson Hospital and Tumor Institute endowed me with the means to find my place in science.  It served me 
very, very well in supporting my career, and the choices I was able to exercise in its subsequent directions. 
There is a Chinese saying: “The journey of 10,000 steps, begins with one step.”  Each of you in the Class of 2000 shares one 
thing with me in that regard.  That one thing is that our first professional mentor placed us on the path and 
walked with us as we began our professional journey.  I would, in this regard, particularly like to acknowl-
edge, with my sincerest gratitude, that the first steps on my 10,000 step career journey resulted from Dr. T.C. 
Hsu extending to me the privilege of working with him as a GSBS student at the M.D. Anderson Hospital and 
Tumor Institute.  His mentorship and that subsequently received from Drs. Darrell Ward and Lubomir Se-
donius Hnilica provided the strong shoulders upon which I stood as I made my contribution to the betterment 
of science and its public health applications.  In our time in science, Dr. Hsu and I have gone from an environ-
ment of science that was struggling to accurately count chromosomes to an environment that just recently was 
able to count the number of genes on chromosomes 21 (225) and 22 (545), and map their locations.  We have 
seen in this time a technology change from simple film-covered glass slide autoradiography to the develop-
ment of complex multidimensional DNA microarray technology for analyzing the symphonic concert of si-
multaneous gene expression patterns in normal and diseased cells and tissues.  It has been a trip beyond my wildest expecta-
tions when I took that first step at the GSBS in 1963.  How I envy the members of the Class of 2000 the journey that they are 
beginning today.  In your journey, and from the place in science you will find, you will see the promise of both yesterday’s 
and today’s science unfold into biomedical and medical applications undreamed of as recently as a few years ago.  I hope 
each of you, the graduates of the GSBS Class of 2000, has a journey as rewarding as mine has been.   
      
Excerpted 6/13/00.  Complete text available, (713) 500-9865. 
 
T. C. Hsu, 
The closing of the genetic century heralds the begin-
ning of the genomic century.  It is here and we are in 
it.  The transition has ushered in new challenges to 
science for ensuring the means of our living and re-
producing responsibly in a healthy global relation-
ship with each other and the environment.  The 
means are at hand and the hands that will apply 
them are the young investigators graduating from 
our nations’ graduate schools this year. 
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GSBS CLASS OF 2000 
 
Master of Science 
 
Edgardo Alicea (Robert Newman, Ph.D.) 
Crotoxin: Membrane Damage and Cell Injury In Ovarian Cancer Cells 
 
Brett Anderson (Constantin Ioannides, Ph.D.) 
Activation Requirements of Peripheral  CD8+ Cells by a Tumor Peptide, E75, HER-2 (p369-377) 
 
Christopher Baird (George Starkschall, Ph.D.) 
Dosimetry of Large-Breasted Patients Utilizing Compensating Filters 
 
Michael Bieda (John Antolak, Ph.D.) 
A Monte Carlo Method for Commissioning Electron Beams 
 
Shannon Bragg-Sitton (Edward Jackson, Ph.D.) 
Assessment of the Reliability and Reproducibility of Functional Magnetic Resonance Imaging for Selected Cognitive 
Tasks 
 
Anna Ruth Carr (Stephen Daiger, Ph.D.) 
Identification and Screening of Candidate Genes for Inherited Eye Diseases 
 
Saleen Chenevert (Linda Cooley, Ph.D.)  
Identification of New Chromosomal Aberrations as Prognostic Indicators for Pediatric Acute Lymphoblastic Leukemia 
 
Yeng-Nee Chu ( Reuben Lotan, Ph.D.) 
Induction of Apoptosis in Human Bladder Transitional Carcinoma Cells by the Synthetic Retinoid CD437  
 
Anthony Costa (Theresa Koehler, Ph.D.) 
Bacteriophage TP21: Studies of Generalized Transduction in Bacillus cereus Group of Species and Physical Analysis of 
the Genome 
 
Andrea Crabtree (Gary Gallick, Ph.D.) 
Overexpression of c-Src in the SW480 Colon Tumor Cell Line Decreases Migration and Increases Invasion 
 
Lei Deng (M. Tien Kuo, Ph.D.) 
2-AAF Up-regulates Rat mdr1b Expression Through Generation of Reactive Oxygen Species that Activate NF-6B 
 
Angela Gibson (Dana Hardin, M.D.) 
Identification and Therapy Efficacy of Type 2Y Diabetes in Hispanics 
 
Hannah Johnson (James Reuben, Ph.D.) 
Interferon-Alpha Restores Cellular Immune Function of Chronic Myelogenous Leukemia Patients 
 
Ni Lu (Benoit de Crombrugghe, M.D., Agrege) 
Structure/Function Analysis of the Transcription Factors L-Sox5 and Sox6 
 
Weiqin Lu (Wallace McKeehan, Ph.D.) 
Fibrolast Growth Factor-10: A Second Candidate Stromal to Epithelial Cell Andromedin in Prostate 
 
Wen Luo (Malcolm Winkler, Ph.D.) 
Regulation of Pyridoxal 5’- Phosphate Biosynthesis in Escherichia coli K-12 
 
 
 
 
-10- 
Warren McClure (Frank Booth, Ph.D.) 
AUF1 Protein Concentration and Binding Activity in Skeletal Muscle are Exercise Responsive and Fiber Type Dependent 
 
Robert Meade (Peter Gascoyne, Ph.D.) 
Dielectric Characterization of c-Src Antisense Transfected HT29 Cells 
 
Roselina Montoya (Marsha Frazier, Ph.D.) 
Perillyl Alcohol Activity on N-Nitrosobis (2-Oxopropyl) Amine-Induced Pancreatic Cancer in the Syrian Golden Hamster 
 
Werner Montross (Pierre McCrea, Ph.D.) 
A $-Catenin/Engrailed Chimera Selectively Suppresses WNT Signaling 
 
Erin Mooney (Pierre McCrea, Ph.D.) 
Cadherin Juxtamembrane Construct Generation: Strategies for Studying Cadherin-Based Structures and Adhesion 
 
Sarah Nemanic (Jocelyne Bachevalier, Ph.D.) 
The Effects of Selective Hippocampal Lesions on Two Tasks of Recognition Memory in Adult Rhesus Monkeys 
 
Amie Ortman (Rebecca Pentz, Ph.D.) 
Development and Evaluation of an Educational Videotape for Individuals at Risk for an Inherited Predisposition to Cancer 
 
Brian Pavey (Frank Booth, Ph.D.) 
The Isolated Skeletal Muscle Incubation System Is Not Suitable for Studying LPL mRNA Decay in Incubated White Vastus 
Lateralis and Soleus Muscles 
 
Leslie Rogers (Ann Killary, Ph.D.) 
Classification of Renal Cell Carcinomas Using cDNA Microarrays as an Alternative to Current Classification Methods 
 
Martha Sandoval (Varsha Gandhi, Ph.D.) 
Alterations in the Expression of Ribonucleotide Reductase Induced by DNA Damage in Human Chronic Lymphocytic Leuke-
mia Cells 
 
Qin Sheng (Malcolm Winkler, Ph.D.) 
Construction and Physiological Study of D-1-Deoxyxylulose-5' -Phosphate Synthase Mutant in Escherichia coli K-12 
 
Tong Sun (Ralph Arlinghaus, Ph.D.) 
Bcr Phosphoserine and Phophotyrosine Specific Antibodies and Their Application in Bcr-Abl/Bcr Interaction 
 
Stacia Vaughn (Jacqueline Hecht, Ph.D.) 
Mapping of the Progressive Diaphyseal Dysplasia (Engelmann Syndrome) Locus to a 6cM Region on Chromosome 19q 13.2. 
 
Debra Wallis (Dianna Milewicz, M.D., Ph.D.) 
Characterization of Fibrillin-1 Microfibrils in Scleroderma 
 
Bruce Williams (Richard Clark, Ph.D.) 
Agonist-Induced Down-Regulation of the  $2 Adrenergic Receptor 
 
Jingyong Zhao (Malcolm Winkler, Ph.D.) 
Overexpression of MutL and MutS Suppresses the GC÷TA Transversion Mutations in Nutrient - Limited Escherichia coli K-
12 
 
Bing Zheng (Grady Saunders, Ph.D.) 
Characterization of a Human PAX6 Gene Enhancer 
 
 
Doctor of Philosophy 
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Sandeep Agarwal (Gailen Marshall, M.D., Ph.D.) 
Role of CD28/B7 Costimulation in the Type-1/Type-2 Cytokine Alterations by Dexamethasone 
 
Larry Anderson (Craig Mullen, M.D., Ph.D.) 
Tumor Immunization Strategies for Enhancing the Graft-Versus-Tumor Activity of Allogeneic Bone Marrow Transplantation 
 
Laura Angelo (Razelle Kurzrock, M.D.) 
Constitutive Expression of Interleukin-6 in Renal Cell Carcinoma is Modulated by p53 
 
Nelson Arango (Richard Behringer, Ph.D.) 
In Vivo Definition of Genetic and Cellular Aspects of Mammalian Sexual Differentiation 
 
Philip Bergman (Catherine O’Brian, Ph.D.) 
Effects of Butyrate on the Colon Cancer Cell Phenotype-Chemosensitization and Upregulation of Proteins Implicated in Can-
cer Progression 
 
Weimin Bi (Benoit de Crombrugghe, M.D., Agrege) 
Functional Analysis of Sox9 in Chondrogenesis by Targeted Gene Inactivation 
 
Zhanyong Bing (Warren Liao, Ph.D.) 
Transcription Factor SEF: Purification and Functional Characterization 
 
Tracy Blevins (Roger Barber, Ph.D.) 
The Two State Model of Receptor Activation: The Agonist and the Efficacy 
 
M. Gabriella Bowden (Heidi Kaplan, Ph.D.) 
The LPS O-Antigen id Required for Myxococcus xanthus : Social Motility and Multicellular Development 
 
Eva Caudell (Elizabeth Grimm, Ph.D.) 
Purification and Cloning of the Novel Phosphoprotein Copine III  and Characterization of its Associated Kinase Activity 
 
Siew-Sim Cheah (Richard Behringer, Ph.D.) 
Analysis of Lim1 LIM Domains in Mouse Development 
 
Belisa Diaz (Gabriel Lopez-Berestein, M.D.) 
A Distinct Element Involved in the Lipopolysaccharide Activation of the Tumor Necrosis Factor-" Promoter in a Promono-
cytic Cell Line, THP-1 
 
David Fenyes (Ponnada Narayana, Ph.D.) 
Diffusion Tensor Imaging of Rat Spinal Cord In vivo 
 
Margaret French (Daniel Carson, Ph.D.) 
A Study of the Biology of Perlecan 
 
Chuan Gao (Jon Wiener, Ph.D.) 
The Effect of Protein Tyrosine Phosphatase SHP1 on Tumorigenicity of the MDA-MB231 Breast Cancer Cells 
 
Weidong Jiang (Margaret Kripke, Ph.D.) 
The Role of p53 in Skin Cancer Induction by UV Irradiation and as a Potential Tumor Antigen in UV-Induced Murine Skin 
Tumors 
 
Kwang-Hwan Jung (John Spudich, Ph.D.) 
Protein-Protein Interaction Between Phototaxis Receptor Sensory Rhodopsin I and its Transducer HtrI  
 
Quinn Kleerekoper (John Putkey, Ph.D.) 
NMR Structural Analysis of Cardiac Troponin C: Monitoring Conformational Changes Induced by Binding Calcium, Tro-
ponin I, and Calcium Sensitizing Drugs 
 
Hilde Lechner (John Byrne, Ph.D.) 
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Behavioral and Cellular Analysis of Classical Conditioning of Feeding Behavior in Aplysia 
 
Wei-Ping Lee (Mien-Chie Hung, Ph.D.) 
AXL-GAS6 Signaling Counteracts Adenovirus 5 E1A-Mediated Cell Growth Suppression and Proapoptotic Activity 
              
Shiaw-Yin Lin (Mien-Chie Hung, Ph.D.) 
Two Prognostic Factors in Breast Cancer: Novel Functions of EGFR and $-Catenin 
 
Bin Liu (David Young, M.D., Ph.D.) 
Characterization of Anti-Sulfatide Autoantibodies in Demyelinating Diseases 
 
Amy Loercher (Ralph Freedman, M.D., Ph.D.) 
The Effects of IL-10 Producing Monocytes on T-Cell Activation in Patients with Epithelial Ovarian Cancer 
 
Xiaolan Ma (William Margolin, Ph.D.) 
Genetic and Functional Analysis of Cell Division Proteins FtsZ and FtsA in Escherichia Coli 
 
Jeanelle Martinez (Lovell Jones, Ph.D.) 
Developmental Effects of Estrogen and PCBs in the Reproductive Tract of BALB/C Mice 
 
Steven McCullough (Richard Wendt, III, Ph.D.) 
A Novel Treatment Planning Methodology for High Dose 166Ho-DOTMP Marrow Ablation Therapy in Patients with Multiple 
Myeloma 
 
Javier Medina (Michael Mauk, Ph.D.) 
Cerebellar Mechanisms for Motor Learning: Testing Predictions from a Large-Scale Computer Simulation 
 
Jennifer Newcomb-Fernandez (Thomas Goka, Ph.D.) 
 Proteolytic Mechanisms of Cell Injury Following Glucose-Oxygen Deprivation in Primary Neuronal Cultures  
 
Mustafa Ozen (Sen Pathak, Ph.D.) 
Delineation of a Novel Genetic Region at 5q11 Harboring Tumor Suppressor Gene(s) and Identification of the Telomeric 
DNA as a Marker for Human Prostate Cancer 
 
Bulent Ozpolat (Lawrence Lachman, Ph.D., M.B.A.) 
Development of a Protective Vaccine Against Helicobacter pylori 
 
Hariyadarshi Pannu (Vicki Huff, Ph.D.) 
Identification and Characterization of Cellular Genes Differentially Expressed in a Subset of Wilms Tumor with Nonfunc-
tional WT1 
 
Michael Pearlman (Dr. Emil Freireich, M.D.) 
The Mechanism of the Pharmacological Actions of Dexrazoxane on Different Tissue Types 
 
Bastianella Perazzona (John Spudich, Ph.D.) 
Role of Transducer Proteins in Phototaxis Signaling of Halobacterium salinarum 
 
Johnny Perez (Barry Kahan, M.D., Ph.D.) 
Tolerance of Allografts Across MHC Barriers by Allochimeric Class I MHC Proteins 
 
Usman Qazi (James Stoops, Ph.D.) 
Structural Studies of Proteinase Entrapment by Human"2-Macroglobulin Using 3-D Electron Microscopy 
 
Brinda Rana (Wen-Hsiung Li, Ph.D.) 
Selection at the MC1R Locus: Contribution to Human Pigmentation Variation 
 
Yongsheng Ren (Warren Liao, Ph.D.) 
Transcriptional Repression of Serum Amyloid A1 by AP-2 Contributes to its Liver-Specific Expression 
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Andrei (Andrew) Rodin (Yun-Xin Fu, Ph.D.) 
New Algorithms for Automated Phylogenetic Reconstruction Using Artificial Intelligence and Data Mining Techniques 
 
David Schmitt (Stephen Ullrich, Ph.D.) 
Dual Role of Interleukin-12 on Ultraviolet-Induced Immune Suppression 
 
Jonathan Stein (Jacob Kagan, Ph.D.) 
The Localization and Identification of Candidate Tumor Suppressor Genes Involved in Prostate Cancer on Chromosome 8p 
 
John Renn Su (Jeffery Jones, Ph.D.) 
Variables Affecting the Stability of Multiple Cloning Sites and Hairpin Structures in Retroviral Vectors 
 
Gulshan Sunavala (Michael Van Dyke, Ph.D.) 
Searching for the Ideal DNA Recognition Code of Covalent Ligands 
 
Ming Tan (Dihua Yu, M.D., Ph.D.) 
The Role of ErbB2 Receptor in Human Breast Cancer Metastasis 
 
Chadwick Thompson (Henry Strobel, Ph.D.) 
Cytochrome P450 2D18 in the Mammalian Brain: Recombinant Expression, Purification, and Characterization of Xenobiotic 
and Endobiotic Metabolism 
 
Jay Vivian (William Klein, Ph.D.) 
Use of a Hypomorphic Allele of Myogenin to Analyze Myogenin-Dependent Processes in Mouse Development  
 
Sung-Ling Wang (Guillermina Lozano, Ph.D.) 
A Novel DNA Damage Inducible Inhibitor of p53 
 
Anjanette Watson (Sharon Roth, Ph.D.) 
Elucidation of Chromatin Mediated Tup1-Ssn6 Repression 
 
Yun Wu (Ralph Arilinghaus, Ph.D.) 
Bcr: A Conditional Inhibitor of Bcr-Abl Oncoprotein 
 
Lixuan Xu (Marsha Frazier, Ph.D.) 
Molecular Basis of Hereditary Nonpolyposis Colorectal Cancer (HNPCC): Mutation Analysis and DNA Methylation Study 
 
Lei Xu (Isaiah Fidler, D.V.M., Ph.D.) 
Ovarian Cancer Angiogenesis, Biology and Therapy 
 
Nianhua Xu (Ann-Bin Shyu, Ph.D.) 
Mechanism of mRNA Stability Control Mediated by Au-Rich Element: Characterization of Cis-Element and Trans-Factor 
 
Jianhua Yang (Bing Su, Ph.D.) 
Biochemical and Genetic Analysis of Two Protein Kinases JNKK2 and MEKK3 
 
Vivian Wei-Chung Yang (Magnus Höök, Ph.D.)  
Interactions and Structural Analysis of the Zinc-Binding Motif in Decorin, a Small Leucine-Rich Proteoglycan in Extracellu-
lar Matrix 
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FACULTY MEMBERSHIP COMMITTEE REPORT 
 
 
 
 
 
 
 
 
 
 
NEW REGULAR MEMBERS: 
 
Lynne V. Abruzzo, Assistant Professor, Department of Hematopathology, M.D. Anderson Cancer Center.  Ph.D., M.D., University of 
Chicago, 1984, 1986.  Research interests:  hematopathology 
Francois X. Claret, Assistant Professor, Department of Molecular Therapeutics, M. D. Anderson Cancer Center.  Ph.D., University of 
Lausanne, 1993.  Research interests:  signal transduction in cancer; JNK/SAPK activation; cellular proliferation and oncogenic transfor-
mation; JAB1 in cell cycle control and ubiquitin/proteasome signaling pathway; apoptosis (Fas/FasL) 
Jiale Dai, Assistant Professor, Department of Molecular Pathology, M. D. Anderson Cancer Center.  Ph.D.,  University of Miami 
School of Medicine, 1997; M.D., Shanghai Medical University, 1989.  Research interests:  tumor suppressor genes; oncogenes; gene 
expression profiles; signal transduction; TGF-beta 
Patrick M. Dougherty, Associate Professor, Department of Anesthesiology, M. D. Anderson Cancer Center.  Ph.D., UT-Houston 
GSBS, 1988.  Research interests:  neurobiology, neurophysiology and neuropharmacology of the spinal dorsal horn; forebrain mecha-
nisms of somatosensation and hyperalgesia; mechanisms of central pain; neural mechanisms of hyperalgesia, chronic fatigue and cogni-
tive impairment due to cancer and cancer therapies; psychophysics and functional imaging of acute, neuropathic and cancer pain in 
humans 
Zhen Fan, Assistant Professor, Department of Experimental Therapeutics, M. D. Anderson Cancer Center.   M.D., Shanghai Medical 
University, 1985.  Research interests:  apoptosis; growth factors; signal transduction 
Jeffrey A. Frost, Assistant Professor, Department of Integrative Biology and Pharmacology, UT-Houston  Medical School.  Ph.D., 
University of California at San Diego, 1993.  Research interests:  signal transduction; small GTP binding proteins; protein phosphoryla-
tion; cell proliferation and transformation 
James E. Hixson, Professor, Department of Human Genetics Center, UT-Houston School of Public Health,  Ph.D., University of 
Michigan, 1983.  Research interests:  molecular genetics; genetics of common disease; gene structure and expression in atherosclerosis 
Jean Pierre Issa, Associate Professor, Department of Leukemia, M. D. Anderson Cancer Center.  M.D., The American University of 
Beirut, 1987.  Research interests:  DNA methylation in normal and neoplastic cells; molecular biology of aging and cancer; tumor-
suppressor genes; epigenetic silencing 
W. David Jarvis, Assistant Professor, Department of Integrative Biology and Pharmacology, UT-Houston  Medical School.  Ph.D., 
University of Virginia Graduate School of Arts and Sciences, 1992.  Research interests:  cancer cell biology; leukemia; lymphoma; 
apoptosis; lethal stress signaling; lipid messengers; molecular pharmacology and experimental therapeutics 
Khandan Keyomarsi, Associate Professor, Department of Experimental Radiation Oncology, M. D. Anderson Cancer Center.  Ph.D., 
University of Southern California (Los Angeles), 1989.  Research interests:  breast cancer; cell cycle control; molecular targeting; drug 
targeting; estrogen receptor; experimental therapeutics 
Yahuan Lou, Associate Professor, Department of Basic Sciences, UT-Houston Dental Branch.  Ph.D., Hokkaido University, 1990.  
Research interests:  autoimmunity; cellular and molecular immunology; animal models for autoimmune disease; T cells and autoanti-
body; inflammation 
Gregory S. May, Professor, Department of Pathology and Laboratory Medicine, M.D. Anderson Cancer Center.   Ph.D., Yale Univer-
sity, 1984.  Research interests:  cell motility; class I myosin; mitosis; cell cycle; chromosome structure 
Jeffrey J. Molldrem, Assistant Professor, Department of Immunology, M. D. Anderson Cancer Center.  M.D., University of Minne-
sota, 1990.  Research interests:  tumor immunity; transplant immunology; T cell tolerance mechanisms 
Renata Pasqualini, Associate Professor, Department of Genitourinary Medical Oncology, M. D. Anderson Cancer Center.  Ph.D., 
MEMBERS APPOINTED WITH COMMENDATION 
 
   Katherine A. Borkovich, Ph.D.    Samuel Kaplan, Ph.D. 
   Peter J. Christie, Ph.D.    Raymond E. Meyn, Jr., Ph.D. 
   William Dowhan, Ph.D.    Dianna M. Milewicz, M.D./Ph.D. 
   Mien-Chie Hung, Ph.D.    Stephen E. Ullrich, Ph.D. 
   Jacob Kagan, Ph.D. 
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University of Sao Paulo, 1990.  Research interests:  polymeric fibronectin as an anti-cancer agent; vascular targeting; vascular biology and 
angiogenesis regulation; au integrin signaling in angiogenesis; a new approach for the immunodiagnostics of breast cancer by random pep-
tide phase display 
Felipe Samaniego, Assistant Professor, Department of Lymphoma/Myeloma, M.D. Anderson Cancer Center.   M.D., Harvard Medical 
School, 1983.  Research interests:  transformation mechanism in viral related cancers; human herpesvirus 8 in lymphoma and Kaposi's sar-
coma; angiogenesis 
Anne B. Sereno, Assistant Professor, Department of Neurobiology and Anatomy, UT-Houston Medical School.  Ph.D., Harvard Univer-
sity, 1991.  Research interests:  attention; short-term memory; eye movements; visual cortex; primates; electrophysiology; schizophrenia; 
Parkinson's disease 
Duen-Hwa Yan, Assistant Professor, Department of Surgical Oncology, M.D. Anderson Cancer Center.  Ph.D., UT-Houston GSBS, 1991.  
Research interests:  cancer gene therapy; gene expression; translational regulation; HER-2/neu; p202; BRCA2 
Pierre Zoldhelyi, Assistant Professor, Department of Internal Medicine, UT-Houston Medical School.  M.D., University of Padua, 1985.  
Research interests:  medicine; cardiology; molecular biology; gene transfer and gene therapy 
 
NEW ASSOCIATE MEMBERS: 
 
Jaroslaw A. Aronowski, Assistant Professor, Department of Neurology, UT-Houston Medical School.  Ph.D., Polish Academy of Sci-
ences, 1992.  Research interests:  animal models of cerebral ischemia; neuroprotection; protein phosphorylation; transcription factors; in-
flammation; neuronal death 
Charles Bloch, Assistant Professor, Department of Radiation Physics, M.D. Anderson Cancer Center.  Ph.D., Michigan State University, 
1987.  Research interests:  radiation physics; proton therapy; sterotactic radiosurgery 
Bang-Ning Lee, Assistant Professor, Department of Laboratory Medicine, M.D. Anderson Cancer Center.   Ph.D., University of Houston, 
1993.  Research interests:  molecular virology; vaccine immunology; cellular and molecular immunology 
Verna M. Rose, Assistant Professor, Department of Pediatrics, UT-Houston Medical School. M.D., Texas A&M University Health Science 
Center, 1988.  Research interests:  X-linked hypophosphatemic rickets; dysmorphology 
William C. Satterfield, Associate Professor, Department of Veterinary Sciences, M.D. Anderson Cancer Center.  D.V.M., Auburn Univer-
sity, 1969. Research interests:  animal models; primates; large animals; farm animals; large animal surgical; toxicological, pharmacody-
namic models; animal care and use regulations 
Ratna K. Vadlamudi, Assistant Professor, Department of Experimental Therapeutics, M.D. Anderson Cancer Center.  Ph.D., University of 
Wyoming, 1994.  Research interests:  growth factor signal transduction; bZip transcription factor ATF4; cell migration/metastasis; focal 
adhesion signaling; regulated exocytosis; P160 and ER signaling 
Changping Zou, Assistant Professor, Department of Obstetrics, Gynecology and Reproductive Sciences, UT-Houston Medical School.  
M.D., Beijing Medical University, 1983; Ph.D., UT-Houston SPH, 1994.  Research interests:  cancer prevention; translational study on 
retinoids and other agents including biological agents in chemoprevention; development of a vaccine against human papillomavirus (HPV) 
infection, which will be used in cancer prevention 
 
 
Alicia J. Dombroski, Ph.D. (left) was named the 
John P. McGovern Outstanding Teacher for 2000 by the Graduate Student Association, 
here with GSA President Athanasia Panopoulos (right).  
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newsletter 
Editor: Linda Carter 
Graduate School of Biomedical Sciences 
P.O.Box 20334   Suite 300 HMC 
The University of Texas-Houston 
Health Science Center 
Houston, Texas 77225-0334 
Address Correction Requested 
UT-H GSBS ALUMNI ASSOCIATION: ALL ABOARD! 
Graduated in 2000?  You’re along for the ride.  Graduated in 1969? You are too, as well as every graduating class in between.  To start 
at the beginning of the Association, credit the Dean (and Dean’s Council) for recommending an able Charter Steering Committee: Ann 
Killary, Ph.D. 1980; Maureen Goode, Ph.D., 1985; Ed Jackson, Ph.D., 1990; Ben Thomas, Ph.D., 1973; and Brenda Whaley, Ph.D., 
1995.  They in turn have elected officers (Ann Killary, President; Maureen Goode, Vice President-Treasurer) and organized by-
laws.  They also agreed that it is most important for the GSBS Alumni Association to be inclusive rather than exclusive in membership, 
which means a no-fee membership for all and a variety of benefits for each of you individually. Mark your calendar early for the inau-
gural GSBS Alumni Association Annual Meeting and Reunion Dinner Reception at the Houston Museum of Health and Medical Sci-
ence on Saturday evening, 6-9 pm, October 14, 2000.  This will be a terrific event (free of charge) and an opportunity for visiting with 
your colleagues and friends.  In the meantime the Steering Committee is developing an interactive WebPage—but more about that later. 
If you have news you would like to share, send it to me at lcarter@gsbs.gs.uth.tmc.edu or UT-Houston GSBS at P.O. Box 20334, Hous-
ton, TX 77225-0334.  Telephone: (713) 500-9865; FAX: (713) 500-9877.  Stay cool and see you in October! 
Celebrating GSBS Commencement are left to 
right: graduate student Patty Wong; new graduate 
Leslie Rogers, Ph.D.; Alumni Association Presi-
dent, Ann Killary, Ph.D., 1980; Dawn Chandler, 
Ph.D., 1998; and  Stephen Lott, Ph.D., 1997.  
(Killary was Advisor to Wong, Rogers, and Lott.)    
